Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male or female, 18 years of age or older.~2. Diagnosis of RA based on the 2010 American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) criteria (as defined in the definition of terms).~3. Rheumatoid Arthritis (RA) diagnosis at least 3 months from the date of first Screening.~4. Have active RA defined by minimum disease activity criteria:~   * ≥ 6 Swollen joints (based on 66 joint counts) at screening and baseline visits.~  * ≥ 6 Tender joints (based on 68 joint counts) at screening and baseline visits.~  * hsCRP\> ULN OR positive for both Rheumatoid Factor (RF) and Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibody levels at screening.~5. Inadequate response to Methotrexate (MTX) treatment defined as oral or parenteral treatment ≥ 3 months with an unchanged mode of application and stable prescribed MTX dose for at least 4 weeks prior to baseline of ≥ 10mg/week and \< the upper limit of the applicable approved local label. Subject can also be on stable doses of sulfasalazine and/or hydroxychloroquine, so long as they are also on methotrexate.~Exclusion Criteria:~1. Subject has previous exposure to Humira, other Tumor necrosis factor (TNF) inhibitors or other biological DMARDs.~2. Current treatment with traditional oral Disease modifying antirheumatic drugs (DMARDs) (except for concomitant treatment with sulfasalazine and/or hydroxychloroquine in addition to MTX). Oral DMARDs must be washed out 5 times the mean terminal elimination half-life of a drug apart from MTX prior to Day 1.~   • Subject could have been exposed to prior Janus kinase (JAK) inhibitors so long as they have been off therapy for 5 half-lives.~3. Stable prescribed dose of oral prednisone or prednisone equivalent \> 10 mg/day within the 30 days of first dose of study drug.~4. Intra-articular or parenteral administration of corticosteroids in the preceding 4 weeks of first dose of study drug. Inhaled corticosteroids for stable medical conditions are allowed.~5. Laboratory values of the following at the Screening Visit:~   * Confirmed hemoglobin \< 9 g/dL for males and \< 8.5 g/dL for females,~  * Absolute neutrophil count (ANC) \< 1500 mm\^3,~  * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 1.5 × the upper limit of normal (ULN) or bilirubin ≥ 3 mg/dL,~  * Serum creatinine \> 1.5 × the ULN,~  * Platelets \< 100,000 cells/\[mm3\] (10\^9/L),~  * Clinically significant abnormal screening laboratory results as evaluated by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Adalimumab 40 mg EOW (Type: ACTIVE_COMPARATOR): Adalimumab 40 mg every other week (EOW) for 11 weeks.
- ABT-122 60 mg EOW (Type: EXPERIMENTAL): ABT-122 60 mg every other week (EOW) for 11 weeks.
- ABT-122 120 mg EOW (Type: EXPERIMENTAL): ABT-122 120 mg every other week (EOW) for 11 weeks.
- ABT-122 120 mg EW (Type: EXPERIMENTAL): ABT-122 120 mg every week (EW) for 11 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).